Search

Your search keyword '"Dinney, Colin"' showing total 2,231 results

Search Constraints

Start Over You searched for: Author "Dinney, Colin" Remove constraint Author: "Dinney, Colin"
2,231 results on '"Dinney, Colin"'

Search Results

1. Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial

2. Rosiglitazone and trametinib exhibit potent anti-tumor activity in a mouse model of muscle invasive bladder cancer

4. Loss of LPAR6 and CAB39L dysregulates the basal-to-luminal urothelial differentiation program, contributing to bladder carcinogenesis

5. Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma.

6. Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract

9. Multicenter evaluation of neoadjuvant and induction gemcitabine–carboplatin versus gemcitabine–cisplatin followed by radical cystectomy for muscle-invasive bladder cancer

10. Lentiviral interferon: A novel method for gene therapy in bladder cancer

12. Single-cell RNA sequencing analysis identifies acute changes in the tumor microenvironment induced by interferon α gene therapy in a murine bladder cancer model.

16. MP16-07 URINARY MINIMAL RESIDUAL DISEASE DETECTION PREDICTS RECURRENCE IN BCG-UNRESPONSIVE NIMBC AND QUANTIFIES MOLECULAR RESPONSE TO NADOFARAGENE FIRADENOVEC

18. PD48-01 EFFICACY OF NADOFARAGENE FIRADENOVEC-VNCG FOR PATIENTS WITH BACILLUS CALMETTE-GUÉRIN-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER: FINAL RESULTS FROM A PHASE 3 TRIAL

24. Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer

28. Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer

30. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer

33. Inferring Bladder Cancer Evolution from Mucosal Field Effects by Whole-Organ Spatial Mutational, Proteomic, and Metabolomic Mapping

36. MORPHOLOGICAL PROGRESSION IN RELAPSING PATIENTS WITH SMALL CELL BLADDER CANCER

37. EFFICACY OF INTRAVESICAL NADOFARAGENE FIRADENOVEC FOR PATIENTS WITH BCG-UNRESPONSIVE CARCINOMA IN SITU OF THE BLADDER: 36-MONTH FOLLOW-UP FROM A PHASE 3 TRIAL

39. Influence of lamina propria invasion extension on T1 high‐grade non‐muscle‐invasive bladder cancer in patients undergoing BCG or radical cystectomy

40. Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry

42. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma

43. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer.

46. Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer

48. Whole-Organ Genomic Characterization of Mucosal Field Effects Initiating Bladder Carcinogenesis

49. Oncolytic Virotherapy Combined with Nivolumab Elicits Complete Responses in Muscle-Invasive Bladder Cancer in Association with the Formation of Tertiary Lymphoid Structures

50. Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33

Catalog

Books, media, physical & digital resources